Treating different types of bladder cancer

Written by: Dr Mark Tuthill
Published:
Edited by: Emma McLeod

If you’ve been diagnosed with bladder cancer (an abnormal growth of cancerous tissue in the bladder), you’ll be looked after by a team of specialists. Mark Tuthill is a leading medical oncologist and an expert in the treatment of cancers, including bladder cancer. Within this article, Dr Tuthill explains the two different types of bladder cancer and how they’re treated.

A patient of 60 years or older in a consultation with his doctor.

 

What are the different types of bladder cancer?

There are two types of bladder cancer. The type you have will affect your course of treatment, as they are managed differently.

  • Non-muscle invasive (superficial) bladder cancer is the more common type and affects the lining of the bladder.
  • Muscle invasive (non-superficial) bladder cancer occurs when non-muscle invasive bladder cancer progresses and involves the muscle of the bladder.

 

How is non-muscle invasive bladder cancer treated?

The treatment of non-muscle invasive (superficial) bladder cancer involves removing the tissue from the lining of the bladder that contains abnormal growth. This happens during a diagnostic procedure called a cystoscopy. During this procedure, a thin tube with a camera (a cystoscope) is inserted into the bladder via the urethra and tools can be passed through it to remove the abnormal tissue.

 

Once treated, patients have regular check-ups to assess their bladder. At these check-ups, they’ll be evaluated for any reoccurrence of abnormal growth in the bladder lining. In some cases, additional treatments such as BCG (a type of immunotherapy drug) or intravesical chemotherapy can be used to prevent reoccurrence.

 

How is muscle-invasive bladder cancer treated?

Muscle-invasive bladder cancer is treated with either surgery or radiotherapy. The objective of both these treatments being to remove any cancerous tissue and therefore remove the disease entirely.

 

In the case of surgery, the bladder is usually removed. With radiotherapy, the cancer cells will be destroyed, leaving healthy cells and tissue with minimal damage.

 

To reduce the likelihood of reoccurrence after surgery, a patient may be recommended a course of chemotherapy before surgery. Chemotherapy can also improve the outcome in people with early muscle-invasive bladder cancer.

 

What’s the best bladder cancer treatment?

The best treatment for bladder cancer depends on the type of cancer that you have.

 

If you have developed muscle-invasive bladder cancer that has recurred after surgery, your medical team will test your tumour for immune activation (this test can be medically referred to as PDL1 testing). If your tumour doesn’t show signs of immune activation, you’ll be recommended to have a course of chemotherapy, followed by a period of observation and then, if the tumour grows again, immunotherapy could be considered.

 

Clinical research

Whether you have developed muscle-invasive or non-muscle invasive bladder cancer, please ask your clinical team if they have any ongoing clinical research that you could take part in. Clinical trials could allow you to have treatments such as molecularly targeted treatments for bladder cancer, which focus on targeting individual cancer growths’ genes, proteins and/or tissues.

 

Dr Mark Tuthill is a medical oncologist in Oxford and very highly practised in the treatment of various cancers. Visit Dr Tuthill’s profile to learn more and to book a consultation.

By Dr Mark Tuthill
Medical oncology

Dr Mark Tuthill is an experienced consultant medical oncologist and an expert in the use of immunotherapy in cancer treatment. Practicing at the Manor Hospital and GenesisCare in Oxford, Dr Tuthill specialises in the treatment of early and recurrent cancer including breast cancer, prostate cancer,kidney cancer, and bladder cancer  Treatment is personalised to each patient's needs and preferences and can include the use of chemotherapy, hormone therapy, immunotherapy, or cancer growth inhibitors.

Dr Tuthill originally qualified from University College London, and trained in Medical Oncology in London at the Royal Marsden, Hammersmith, Charing Cross, and the Chelsea and Westminster Hospitals. In 2015 he was appointed Consultant Medical Oncologist at Churchill Hospital, Oxford, where he acts as principal investigator on a number of clinical trials.

Dr Tuthill’s research interests include tumour immunology, cancer-growth inhibitors, and novel therapeutic drug combinations for the treatment of cancer. He is a principal investigator or sub-investigator for early and late phase clinical trials in tumour types including breast cancer, urological cancers and other tumour types. Dr Tuthill holds a PhD in Tumour Immunology from Imperial College London and regularly presents his research at national and international conferences. He is a clinical ambassador for UCARE (Urology Cancer Research and Education), an independent charity raising funds for research into prostate and bladder cancer, and is a member of The Association of Cancer Physicians.

Dr Tuthill has a medico-legal practice supported by a dedicated a highly professional medico-legal administrative team and medico-legal analysts. He writes clear concise reports to time and client satisfaction.

View Profile

Overall assessment of their patients


This website uses its own and third-party cookies to collect information in order to improve our services, to show you advertising related to your preferences, as well as to analyse your browsing habits..